United Kingdom immune thrombocytopenia registry: Retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings

British Journal of Haematology

Volumn 169, Issue 4, 2015, Pages 590-594

  Rizvi, Hasan ^a,b   Butler, Tom ^b,c   Calaminici, Mariarita ^a,b   Doobaree, Indraraj U ^b   Nandigam, Raghava C ^b   Bennett, Dimitri ^d   Provan, Drew ^b   Newland, Adrian C ^b,c  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Bone marrow fibrosis; Co morbidities; Collagen fibrosis; Primary immune thrombocytopenia; Reticulin fibrosis

Indexed keywords

RETICULIN; MPL PROTEIN, HUMAN; THROMBOPOIETIN RECEPTOR;

ADULT; ANXIETY DISORDER; ARTERIAL THROMBOEMBOLISM; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; BONE MARROW BIOPSY; CANDIDIASIS; CATARACT; CLINICAL ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CUSHING SYNDROME; DEPRESSION; DISEASE CLASSIFICATION; DISEASE REGISTRY; DISEASE SEVERITY; ETHNICITY; FEMALE; HELICOBACTER INFECTION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOTHYROIDISM; KIDNEY DISEASE; LIVER DISEASE; MALE; MYELOFIBROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; PNEUMONIA; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; SOLID TUMOR; SPLENOMEGALY; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID DISEASE; UNITED KINGDOM; VENOUS THROMBOEMBOLISM; ADOLESCENT; AGED; AGONISTS; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PRIMARY MYELOFIBROSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; REGISTER; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; ADULT; AGED; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, THROMBOPOIETIN; REGISTRIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84928423591     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13330     Document Type: Article

References (15)

1. Bauermeister, D.E. (1971) Quantitation of bone marrow reticulin - a normal range. American Journal of Clinical Pathology, 56, 24-31.
2. Beckman, E.N. & Brown, A.W. Jr (1990) Normal reticulin level in iliac bone marrow. Archives of Pathology and Laboratory Medicine, 114, 1241-1243.
3. Boiocchi, L., Orazi, A., Ghanima, W., Arabadjief, M., Bussel, JB, & Geyer, JT. Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities. Mod Pathol 2012;25(1):65-74.
4. Brynes, R., Orazi, A., Verma, S., Brainsky, A., Bailey, C. & Bakshi, K. (2011) Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenic purpura (ITP) treated with eltrombopag - data from the EXTEND study. Blood (ASH Annual Meeting Abstracts), 118, 528. (Abstract)
5. Bussel, JB., Kuter, DJ., Pullarkat, V., Lyons, R.M., Guo, M., Nichol, JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood, 2009;113:2161-2171.
6. Ettrup, M.S., Jensen, A.O., Engebjerg, M.C., Farkas, D.K., Norgaard, M., Cha, S., Zhao, S., Johansen, P. & Sorensen, H.T. (2010) Bone marrow reticulin and collagen content in patients with adult chronic immune thrombocytopenic purpura: a Danish nationwide study. American Journal of Hematology, 85, 930-934.
7. Ghanima, W., Geyer, J.T., Lee, C.S., Boiocchi, L., Imahiyerobo, A.A., Orazi, A. & Bussel, J.B. (2014) Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica, 99, 937-944.
8. Hill, A.B. (1965) The environment and disease: association or causation? Proceedings of the Royal Society of Medicine, 58, 295-300.
9. Kirito, K. & Komatsu, N. (2013) [Progression of bone marrow fibrosis with reticulin and collagen hyperplasia during treatment with the thrombopoietin receptor agonist romiplostim in a patient with immune thrombocytopenia]. Rinsho Ketsueki, 54, 295-299.
10. Kuter, D.J., Bain, B., Mufti, G., Bagg, A. & Hasserjian, R.P. (2007) Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. British Journal of Haematology, 139, 351-362.
11. Kuter, D.J., Mufti, G.J., Bain, B.J., Hasserjian, R.P., Davis, W. & Rutstein, M. (2009) Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood, 114, 3748-3756.
12. Mufti, G., Hasserjian, R., Bain, B., et al. Bone marrow reticulin in patients with immune thrombocytopenic purpura (abstract). Blood, 2006; 108 (11):73b, abstract 3982.
13. Rodeghiero, F., Stasi, R., Giagounidis, A., Viallard, J.F., Godeau, B., Pabinger, I., Cines, D., Liebman, H., Wang, X. & Woodard, P. (2013) Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. European Journal of Haematology, 91, 423-436.
14. Saleh, M.N., Bussel, J.B., Cheng, G., Meyer, O., Bailey, C.K., Arning, M. & Brainsky, A. (2013) Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood, 121, 537-545.
15. Thiele, J., Kvasnicka, H.M., Facchetti, F., Franco, V., van der Walt, J. & Orazi, A. (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica, 90, 1128-1132.